InsidersTradesSigma
泽璟制药: management transactions · France · AMF
SSE:688266FR·AMFMcap 24.5Bn€
Browse the full insider trade history of 泽璟制药, a listed equity based in France. Shares are quoted on FR FR, under the authority of AMF. Market capitalisation: €24.5bn. The latest transaction was reported on 16 April 2026 — Sale. Among the most active insiders: ZELIN SHENG(盛泽林). Every trade is accessible without an account.
32
Insider Decl.
0
Thresholds
·
31 ops.
Buy Volume
€3m
1 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
98.31 €
Income statement
Revenue810.5 M€
Gross profit732.9 M€90% margin
Net income−162.9 M€-20.1% margin
Balance sheet & cash
Market cap24.54 Bn€
Total debt1.13 Bn€
Free Cash Flow−210.2 M€
Last declaration on 16 April 2026
Declarations32 total
Executives●Purchase14SSE
1,784 shares
A股XSHG
SSE:173000005692962100·
Ideal exit: 14 Apr 2023 (T+270)
Executives●Purchase18SSE
200 shares
A股XSHG
SSE:173000005662820540·
Ideal exit: 3 Apr 2023 (T+270)
Executives●Purchase22SSE
2,079 shares
A股XSHG
SSE:173000005659772930·
Ideal exit: 2 Apr 2023 (T+270)
Executives●Purchase14SSE
1,050 shares
A股XSHG
SSE:173000005649137920·
Ideal exit: 28 Mar 2023 (T+270)
Executives●Purchase22SSE
2,360 shares
A股XSHG
SSE:173000005649150940·
Ideal exit: 28 Mar 2023 (T+270)
Executives●Purchase14SSE
2,000 shares
A股XSHG
SSE:173000005547914300·
Ideal exit: 18 Feb 2023 (T+270)
Executives●Purchase7SSE
920 shares
A股XSHG
SSE:173000005547914780·
Ideal exit: 18 Feb 2023 (T+270)
Executives●Purchase22SSE
8,000 shares
A股XSHG
SSE:173000005547913570·
Ideal exit: 18 Feb 2023 (T+270)
Executives●Purchase18SSE
3,500 shares
A股XSHG
SSE:173000005539713440·
Ideal exit: 13 Feb 2023 (T+270)
Executives●Purchase7SSE
27,380 shares
A股XSHG
SSE:173000005378757300·
Ideal exit: 17 Dec 2022 (T+270)
Executives●Purchase14SSE
2,000 shares
A股XSHG
SSE:173000005367543580·
Ideal exit: 11 Dec 2022 (T+270)
Executives●Purchase10SSE
30,000 shares
A股XSHG
SSE:173000005367546620·
Ideal exit: 11 Dec 2022 (T+270)
Executives●Purchase14SSE
11,000 shares
A股XSHG
SSE:173000005365277760·
Ideal exit: 10 Dec 2022 (T+270)
Executives●Purchase11SSE
8,820 shares
A股XSHG
SSE:173000005365279170·
Ideal exit: 10 Dec 2022 (T+270)
Executives●Purchase7SSE
7,000 shares
A股XSHG
SSE:173000005361184800·
Ideal exit: 9 Dec 2022 (T+270)
25 of 32 declarations
About 泽璟制药
Zai Lab is a company focused on developing innovative medicines, particularly in oncology. It is listed on the Shanghai Stock Exchange.